Multiple Vitamins (pediatric) Single Dose Vial Kit
FDA Label NDC 60505-6190

Multiple vitamins injection (pediatric) is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition.

The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy.

Multiple vitamins injection (pediatric) is a combination product that contains the following vitamins: ascorbic acid, vitamin A, vitamin D, thiamine, riboflavin, pyridoxine, niacinamide, dexpanthenol, vitamin E, vitamin K₁, folic acid, biotin, and vitamin B₁₂.

Multiple vitamins injection (pediatric) is supplied as a single dose for intravenous use intended for administration by intravenous infusion after dilution:

• Multiple vitamins injection (pediatric) Single Dose consists of two vials. A weight-based volume from each vial must be added directly to dextrose or saline solution prior to intravenous administration [see Dosage and Administration (2.2 and 2.3)].

The recommended daily dosage volume is based on the patient's actual weight: less than 1 kg, 1 kg to less than 3 kg, and 3 kg or greater.

Patients with multiple vitamin deficiencies or with increased vitamin requirements may need multiple daily dosages as indicated or additional doses of individual vitamins. Supplemental vitamin A may be required for low-birth weight infants.

Additional daily dosages of Vitamin E in infants are not recommended [see Warnings and Precautions (5.8)].

Multiple vitamins injection (pediatric) Single Dose (see Table 1):

One daily dose of Vial 1 (1.2 mL, 2.6 mL or 4 mL) and one daily dose of Vial 2 (0.3 mL, 0.65 mL or 1 mL) based on the patient’s weight are added directly to a specified volume of an intravenous fluid [see Dosage and Administration (2.3)] (see Table 1).

Do not administer multiple vitamins injection (pediatric) as a direct, undiluted intravenous injection as it may cause dizziness, faintness, and possible tissue irritation.

•  Multiple vitamins injection (pediatric) Single Dose:
• Use only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area).
•  Add one weight-based dose of Vial 1 (1.2 mL, 2.6 mL or 4 mL) and one weight-based dose of Vial 2 (0.3 mL, 0.65 mL or 1 mL) directly to at least 100 mL of intravenous dextrose or saline solution.
• Discard unused portion.
• Visually inspect for particulate matter and discoloration prior to administration.
• After multiple vitamins injection (pediatric) is diluted in an intravenous infusion, refrigerate the resulting solution unless it is to be used immediately, and use the solution within 24 hours after dilution.
• Minimize exposure to light because some of the vitamins in multiple vitamins injection (pediatric), particularly A, D and riboflavin, are light sensitive.

Blood vitamin concentrations should be monitored to ensure maintenance of adequate levels, particularly in patients receiving parenteral multivitamins as the only source of vitamins for long periods of time.

• Multiple vitamins injection (pediatric) is not physically compatible with moderately alkaline solutions such as a sodium bicarbonate solution and other alkaline drugs such as acetazolamide sodium, aminophylline, ampicillin sodium, tetracycline HCl and chlorothiazide sodium.
• Folic acid is unstable in the presence of calcium salts such as calcium gluconate.
• Vitamin A and thiamine in multiple vitamins injection (pediatric) may react with bisulfite solutions such as sodium bisulfite or vitamin K bisulfite.
• Do not add multiple vitamins injection (pediatric) directly to intravenous fat emulsions.
• Consult appropriate references for additional listings of physical and chemical compatibility of solutions and drugs with the vitamin infusion when needed. If incompatibilities are identified, avoid admixture or Y-site administration with vitamin solutions.

Multiple vitamins injection (pediatric) Single Dose is an injection consisting of two single-dose vials labeled Vial 1 (4 mL) and Vial 2 (1 mL). For the vitamin strengths [see Dosage and Administration (2.2) and Description (11)].

Vial 1 (Single Dose) is supplied as clear, yellow to orange colored solution in amber glass vial closed with a rubber stopper, aluminum flip-off seals of blue color button.  

Vial 2 (Single Dose) is supplied as clear, off-white to pale yellow colored solution in amber glass vial closed with a rubber stopper, aluminum flip-off seals of pink mat top.

Multiple vitamins injection (pediatric) is contraindicated in patients who have:

• An existing hypervitaminosis, or
• A history of hypersensitivity to any vitamins or excipients contained in this formulation.

Multiple vitamins injection (pediatric) contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration in pediatric patients with renal impairment. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solution, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration. To prevent aluminum toxicity periodically monitor aluminum levels with prolonged parenteral administration of multiple vitamins injection (pediatric).

Allergic reactions such as urticaria, shortness of breath, wheezing and angioedema have been reported following intravenous administration of thiamine, which is found in multiple vitamins injection (pediatric). There have been rare reports of anaphylaxis following intravenous doses of thiamine. No fatal anaphylaxis associated with multiple vitamins injection (pediatric) has been reported.

Hypervitaminosis A, manifested by nausea, vomiting, headache, dizziness, blurred vision has been reported in patients with renal failure receiving 1.5 mg/day retinol and in patients with liver disease. Therefore, supplementation of renal failure patients and patients with liver disease with vitamin A, an ingredient found in multiple vitamins injection (pediatric), should be undertaken with caution [see Use in Specific Populations (8.6 and 8.7)]. Blood levels of Vitamin A should be monitored periodically.

Multiple vitamins injection (pediatric) contains Vitamin K which may decrease the anticoagulant action of warfarin. In patients who are on warfarin anticoagulant therapy receiving multiple vitamins injection (pediatric) monitor blood levels of prothrombin/INR to determine if dose of warfarin needs to be adjusted.

Multiple vitamins injection (pediatric) contains folic acid and cyanocobalamin which can mask serum deficiencies of folic acid and cyanocobalamin in patients with megaloblastic anemia. Avoid the use of multiple vitamins injection (pediatric) in patients with suspected or diagnosed megaloblastic anemia prior to blood sampling for the detection of the folic acid and cyanocobalamin deficiencies.

In patients receiving parenteral multivitamins such as with multiple vitamins injection (pediatric), blood vitamin concentrations should be periodically monitored to determine if vitamin deficiencies or excesses are developing. Multiple vitamins injection (pediatric) may not correct long-standing specific vitamin deficiencies. The administration of additional doses of specific vitamins may be required [see Dosage and Administration (2.2)].

Multiple vitamins injection (pediatric) contains vitamin C which is also known as ascorbic acid. Ascorbic acid in the urine may cause false negative urine glucose results.

Additional vitamin E supplementations of patients receiving multiple vitamins injection (pediatric) may result in elevated blood concentrations of vitamin E and potential vitamin E toxicity in infants. Avoid additional oral or parental doses of vitamin E in infants. Daily dose of multiple vitamins injection (pediatric) contains adequate concentrations of vitamin E required to achieve normal blood levels of vitamin E.

Lower vitamin A concentrations may occur after administration of multiple vitamins injection (pediatric) due to the adherence of Vitamin A to plastic. Monitor blood vitamin A concentrations periodically. Additional administration of therapeutic doses of vitamin A may be required, especially in low-birth weight infants.

E-Ferol syndrome manifested by thrombocytopenia, renal dysfunction, hepatomegaly, cholestasis, ascites, hypotension and metabolic acidosis has been reported in low-birth weight infants following administration of polysorbates which are found in multiple vitamins injection (pediatric). No E-Ferol syndrome associated with multiple vitamins injection (pediatric) has been reported.

The following adverse reactions are discussed in greater detail in other sections of the labeling.

• Allergic reactions to thiamine [see Warnings and Precautions (5.2)].
• Hypervitaminosis A [see Warnings and Precautions (5.3)]

The following adverse reactions have been identified during postapproval use of multiple vitamins injection (pediatric). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

•  Dermatologic: rash, erythema, pruritis
•  CNS: headache, dizziness, agitation, anxiety
•  Ophthalmic: diplopia

A number of interactions between vitamins and drugs have been reported. The following are examples of these types of interactions.

•  Warfarin: Vitamin K, a component of multiple vitamins injection (pediatric), antagonizes the anticoagulant action of warfarin. In patients who are co-administered warfarin and multiple vitamins injection (pediatric), blood levels of prothrombin/INR should be monitored to determine if dose of warfarin needs to be adjusted [see Warnings and Precautions (5.4)].
•  Antibiotics: Thiamine, riboflavin, pyridoxine, niacinamide, and ascorbic acid decrease antibiotic activities of erythromycin, kanamycin, streptomycin, doxycycline, and lincomycin.
•  Bleomycin: Ascorbic acid and riboflavin inactivate bleomycin in vitro, thus the activity of bleomycin may be reduced.
•  Levodopa: Pyridoxine may increase the metabolism of levodopa (decrease blood levels of levodopa) and decrease its efficacy.
•  Phenytoin: Folic acid may increase phenytoin metabolism and lower the serum concentration of phenytoin resulting in increased seizure activity.
•  Methotrexate: Folic acid may decrease a patient’s response to methotrexate therapy.

•  Hydralazine, Isoniazid: Concomitant administration of hydralazine or isoniazid may increase pyridoxine requirements.
•  Phenytoin: Phenytoin may decrease serum folic acid concentrations.

Risk Summary

Administration of the approved recommended dose of multiple vitamins injection (pediatric) in parental nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. Pregnant patients should follow the U.S. Recommended Daily Allowances for pregnancy because their vitamin requirements may exceed those of nonpregnant patients. Deficiency of essential vitamins may result in adverse pregnancy outcomes (see Clinical Considerations). Animal reproduction studies have not been conducted with multiple vitamins injection (pediatric).  

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.  

Clinical Considerations  

Disease-associated Maternal and/or Embryo-Fetal Risk

Deficiency of essential vitamins has been associated with adverse pregnancy and fetal outcomes, such as maternal folic acid deficiency and an increased risk of neural tube defects. Therefore, parenteral nutrition with multiple vitamins injection should be considered if a pregnant patient’s nutritional requirements cannot be fulfilled by oral or enteral intake.

Risk Summary

Multiple vitamins present in multiple vitamins injection (pediatric) are also present in human milk. Administration of the approved recommended dose of multiple vitamins injection (pediatric) in parental nutrition is not expected to cause harm to a breastfed infant. There is no information on the effects of multiple vitamins injection (pediatric) on milk production. Lactating patients should follow the U.S. Recommended Daily Allowances for their condition, because their vitamin requirements may exceed those of nonlactating patients. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for multiple vitamins injection (pediatric) and any potential adverse effects on the breastfed child from multiple vitamins injection (pediatric) or from the underlying maternal condition.

Multiple vitamins injection (pediatric) is approved for the prevention of vitamin deficiency in pediatric patients up to 11 years old receiving parenteral nutrition. Multiple vitamins injection (pediatric) has not been studied in pediatric patients older than 11 years.

Multiple vitamins injection (pediatric) contains aluminum that may be toxic for premature neonates. Aluminum levels should be monitored periodically during administration of multiple vitamins injection (pediatric) to premature neonates [see Warnings and Precautions (5.1)].

Additional vitamin E supplementations of infants receiving multiple vitamins injection (pediatric) may result in elevated blood concentrations of vitamin E and potential vitamin E toxicity [see Warnings and Precautions (5.8)].

E-Ferol syndrome has been reported in low-birth weight infants following administration of polysorbates which are found in multiple vitamins injection (pediatric). No E-Ferol syndrome associated with multiple vitamins injection (pediatric) has been reported [see Warnings and Precautions (5.10)].

Multiple vitamins injection (pediatric) has not been studied in patients with renal impairment. Monitor renal function, calcium, phosphorus and vitamin A levels in patients with renal impairment [see Warnings and Precautions (5.1 and 5.3)].

Multiple vitamins injection (pediatric) has not been studied in patients with liver impairment. Monitor vitamin A levels in patients with liver disease [see Warnings and Precautions (5.3)].

Signs and symptoms of acute or chronic overdosage may be those of individual multiple vitamins injection (pediatric) component toxicity. There is no clinical experience with multiple vitamins injection (pediatric) overdosage.

Multiple vitamins injection (pediatric) is a sterile product consisting of two vials provided as a single dose for intravenous use intended for administration by intravenous infusion after dilution:

Multiple vitamins injection (pediatric) supplied as single dose consists of:

• (a)Vial 1 (4 mL); and
• (b)Vial 2 (1 mL).

Vial 1 will provide one daily dose of 1.2 mL, 2.6 mL or 4 mL and Vial 2 will provide one daily dose of 0.3 mL, 0.65 mL or 1 mL [see Dosage and Administration (2.2)].

Each 4 mL of Vial 1 contains 10 vitamins and each 1 mL of Vial 2 contains 3 vitamins (see Table 3).

Table 3: Ingredients in Multiple Vitamins Injection (Pediatric) Formulation

Vial 1
Active Ingredient	Quantity per 4 mL
Ascorbic acid (Vitamin C)	80 mg
Vitamin A* (as palmitate)	2,300 IU (equals 0.7 mg)
Vitamin D3* (cholecalciferol)	400 IU (equals 10 mcg)
Thiamine (Vitamin B1) (as the hydrochloride)	1.2 mg
Riboflavin (Vitamin B2) (as riboflavin 5-phosphate sodium)	1.4 mg
Pyridoxine HCl (Vitamin B6)	1 mg
Niacinamide	17 mg
Dexpanthenol (as d-pantothenyl alcohol)	5 mg
Vitamin E* (dl-α-tocopheryl acetate)	7 IU (equals 7 mg)
Vitamin K1 *	0.2 mg

*Polysorbate 80 is used to water solubilize the oil-soluble vitamins A, D, E, and K.

Inactive ingredients in 4 mL of Vial 1: 50 mg polysorbate 80, sodium hydroxide and/or hydrochloric acid for pH adjustment, and water for injection.

Vial 2
Active Ingredient	Quantity per 1 mL
Folic acid	140 mcg
Biotin	20 mcg
Vitamin B12 (cyanocobalamin)	1 mcg

Inactive ingredients in 1 mL of Vial 2: 75 mg mannitol, citric acid and/or sodium citrate for pH adjustment and water for injection.  

Multiple vitamins injection (pediatric) makes available a combination of oil-soluble and water-soluble vitamins in an aqueous solution, formulated for incorporation into intravenous solutions. The liposoluble vitamins A, D, E, and K have been solubilized in an aqueous medium with polysorbate 80, permitting intravenous administration of these vitamins.  

Multiple vitamins injection (pediatric) contains no more than 170 mcg/L of aluminum (combined Vials 1 and 2).

Carcinogenicity, mutagenicity, and fertility studies have not been performed with multiple vitamins injection (pediatric).

How Supplied

Multiple vitamins injection (pediatric) is supplied as follows:

Vial 1 (Single Dose) is supplied as clear, yellow to orange colored solution in amber glass vial closed with a rubber stopper, aluminum flip-off seals of blue color button.

Vial 2 (Single Dose) is supplied as clear, off-white to pale yellow colored solution in amber glass vial closed with a rubber stopper, aluminum flip-off seals of pink mat top.

Multiple vitamins injection (pediatric) Single Dose:

one Vial 1 plus one Vial 2 to be used for a single dose [see Dosage and Administration (2.2, and 2.3)].

Storage and Handling

Minimize exposure of multiple vitamins injection (pediatric) to light because vitamins A, D and riboflavin are light sensitive.

Store under refrigeration, 2°C to 8°C (36°F to 46°F).

Instruct caregiver(s) and patients (if age appropriate):

• To watch for signs of allergic reactions such as urticaria, shortness of breath, wheezing and angioedema since hypersensitivity reactions may occur to any of the vitamins or excipients contained in multiple vitamins injection (pediatric).
• To watch for and immediately report nausea, vomiting, headache, dizziness, blurred vision, especially if patients have renal impairment, as these may be signs of hypervitaminosis A.
• To report other adverse reactions that patients may experience such as rash, erythema, pruritus, headache, dizziness, agitation, anxiety, and diplopia.
• Patients on warfarin anticoagulant therapy will be monitored periodically with blood prothrombin/ INR levels to determine if the dose of warfarin needs to be adjusted.
• About the significance of periodic monitoring of blood vitamin concentrations to determine if vitamin deficiencies or excesses are developing and the need to monitor renal function, calcium, phosphorus, aluminum and vitamin A levels in patients with renal impairment.
• That multiple vitamins injection (pediatric) should be avoided in patients with suspected or diagnosed megaloblastic anemia prior to blood sampling for the detection of the folic acid and cyanocobalamin deficiencies.
• That vitamin C (ascorbic acid) contained in multiple vitamins injection (pediatric) may cause false negative urine glucose results.

Manufactured by:	Manufactured for:
Gland Pharma Limited	Apotex Corp.
Hyderabad, Telangana – 500 043, India	Weston, Florida
ML No. 103/AP/RR/97/F/R	33326

Revised: January 2026 

Rev. 03

4 mL

NDC 60505-6297-1

Multiple Vitamins Injection

(Pediatric)             Vial 1

Single-Dose Vial - Sterile      R_X Only

DILUTE VIALS 1 AND 2 IN NOT LESS THAN 100 ML INFUSION FLUID. 

Pediatricvial-1.jpg (Pediatricvial 1)

1 mL

NDC 60505-6298-2

Multiple Vitamins Injection

(Pediatric)              Vial 2

Single-Dose Vial - Sterile       R_X Only

Pediatricvial-2.jpg (Pediatricvial 2)

NDC 60505-6190-0

Multiple Vitamins Injection

(Pediatric)

For intravenous infusion after dilution only.

Sterile

Contains 5 each of Vial 1 (4 mL) and Vial 2 (1 mL). One vial of each to be used for a single dose.

Store under refrigeration, 2°C to 8°C (36°F to 46°F).

APOTEX CORP. R_X Only

Pediatric-carton.jpg (Pediatric Carton)